BioNTech's Oncology Ambitions Take Center Stage at Major Cancer Conference

BioNTech reveals promising early data for a new HER3-targeted lung cancer drug and a major corporate restructuring, as it shifts focus from COVID-19 to oncology.

BioNTech SE unveiled its most comprehensive set of oncology data to date at the European Lung Cancer Congress in Copenhagen. The presentation highlighted the company's expanding pipeline, with a particular focus on a previously undisclosed clinical candidate, underscoring its strategic pivot beyond its COVID-19 vaccine success.

A New Candidate Emerges with Promising Early Results

The spotlight fell on BNT326/YL202, an HER3-targeted antibody-drug conjugate developed in partnership with MediLink Therapeutics. For the first time, BioNTech shared clinical data showing the candidate exhibited antitumor activity and a manageable safety profile in patients with advanced or metastatic non-small cell lung cancer (NSCLC) whose disease had progressed after standard treatments. These early findings support an ongoing Phase 1b/2 trial exploring a combination of BNT326/YL202 with pumitamig, a PD-L1xVEGF-A immunomodulator. This "novel-novel" combination therapy represents a key part of BioNTech's parallel development strategy alongside its monotherapy programs.

The company also provided updated results from the PRESERVE-003 Phase 3 trial investigating gotistobart in squamous cell lung carcinoma. In a non-pivotal dose-confirmation phase, the treatment demonstrated a 54% reduction in the risk of death compared to standard chemotherapy. These results are considered preliminary, as the pivotal portions of the study are ongoing and require confirmatory data before any regulatory conclusions can be drawn.

Financial Context and Strategic Shifts

This clinical progress unfolds against a challenging financial backdrop. BioNTech reported a net loss of €1.136 billion for 2025 on revenues of €2.87 billion. Its revenue forecast for 2026 is set even lower, at just €2.0 to €2.3 billion, increasing the pressure on the oncology pipeline to justify substantial research expenditures.

Concurrently, a significant corporate restructuring is underway. Founders Ugur Sahin and Özlem Türeci plan to establish a separate entity dedicated to next-generation mRNA innovations. BioNTech intends to contribute relevant rights and technologies to this venture, with a binding agreement targeted for signing by the end of the first half of 2026.

A Broad Clinical Portfolio with Key Milestones Ahead

BioNTech has established an extensive lung cancer research effort, with 16 active clinical studies. This portfolio includes four pivotal Phase 3 programs and five novel-novel combination trials. Management aims to have 15 Phase 3 studies underway by the end of 2026. The current year is critical, with seven major data readouts from late-stage trials scheduled. These results will serve as a tangible benchmark for the success of the company's post-pandemic strategy.

Investors are watching closely, as the stock currently trades approximately 28% below its 52-week high. The upcoming data releases will be pivotal in determining whether the clinical pipeline validates this valuation gap or provides the catalyst to close it.